Impact of EGFR Genetic Variants on Glioma Risk and Patient Outcome

• Tipo: Artigo em Revista Científica Internacional
• Data: 2011

Autores

Bruno Marques Costa (Autor) Outra; Marta Viana Pereira (Autor) Outra; Ricardo Fernandes (Autor) Outra; Sandra Costa (Autor) Outra; Paulo Linhares (Autor) Outra; Rui Vaz (Autor) Outra; Celine Pinheiro (Autor) Outra; Jorge Lima (Autor) FMUP; Paula Soares (Autor) FMUP; Ana Silva (Autor) Outra; Fernando Pardal (Autor) Outra; Julia Amorim (Autor) Outra; Rui Nabico (Autor) Outra; Rui Almeida (Autor) Outra; Carlos Alegria (Autor) Outra; Manuel Melo Pires (Autor) ICBAS; Celia Pinheiro (Autor) Outra; Ernesto Carvalho (Autor) Outra; Pedro Oliveira (Autor) ICBAS; Jose M Lopes (Autor) FMUP; Rui M Reis (Autor) Outra

Revista

Título: Cancer Epidemiology Biomarkers and Prevention

Vol. 20

Páginas: 2610-2617

ISSN: 1055-9965

Editora: American Association for Cancer Research

Indexação

ISI Web of Knowledge - 30 Citações

Scopus - 35 Citações

Classificação Científica

FOS: Ciências médicas e da saúde > Medicina clínica

Outras Informações

ID Authenticus: P-002-HYY

DOI: 10.1158/1055-9965.epi-11-0340

Abstract (EN): Background: The epidermal growth factor receptor (EGFR) regulates important cellular processes and is frequently implicated in human tumors. Three EGFR polymorphisms have been described as having a transcriptional regulatory function: two single-nucleotide polymorphisms in the essential promoter region, -216G/T and -191C/A, and a polymorphic (CA)(n) microsatellite sequence in intron 1. We aimed to elucidate the roles of these EGFR polymorphisms in glioma susceptibility and prognosis. Methods: We conducted a case-control study with 196 patients with glioma and 168 cancer-free controls. Unconditional multivariate logistic regression models were used to calculate ORs and 95% confidence intervals. A Cox regression model was used to evaluate associations with patient survival. False-positive report probabilities were also assessed. Results: None of the EGFR -216G/T variants was significantly associated with glioma risk. The -191C/A genotype was associated with higher risk for glioma when the (CA)(n) alleles were classified as short for -16 or -17 repeats. Independently of the (CA) n repeat cutoff point used, shorter (CA) n repeat variants were significantly associated with increased risk for glioma, particularly glioblastoma and oligodendroglioma. In all tested models with different (CA) n cutoff points, only -191C/A genotype was consistently associated with improved survival of patients with glioblastoma. Conclusions: Our findings implicate EGFR -191C/A and the (CA) n repeat polymorphisms as risk factors for gliomas, and suggest -191C/A as a prognostic marker in glioblastoma. Impact: Our data support a role of these EGFR polymorphisms in determining glioma susceptibility, with potential relevance for molecularly based stratification of patients with glioblastoma for individualized therapies. Cancer Epidemiol Biomarkers Prev; 20(12); 2610-7. (C) 2011 AACR.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 8